COVID19 coagulopathy in Caucasian patients
- PMID: 32330308
- PMCID: PMC7264579
- DOI: 10.1111/bjh.16749
COVID19 coagulopathy in Caucasian patients
Abstract
Although the pathophysiology underlying severe COVID19 remains poorly understood, accumulating data suggest that a lung-centric coagulopathy may play an important role. Elevated D-dimer levels which correlated inversely with overall survival were recently reported in Chinese cohort studies. Critically however, ethnicity has major effects on thrombotic risk, with a 3-4-fold lower risk in Chinese compared to Caucasians and a significantly higher risk in African-Americans. In this study, we investigated COVID19 coagulopathy in Caucasian patients. Our findings confirm that severe COVID19 infection is associated with a significant coagulopathy that correlates with disease severity. Importantly however, Caucasian COVID19 patients on low molecular weight heparin thromboprophylaxis rarely develop overt disseminated intravascular coagulation (DIC). In rare COVID19 cases where DIC does develop, it tends to be restricted to late-stage disease. Collectively, these data suggest that the diffuse bilateral pulmonary inflammation observed in COVID19 is associated with a novel pulmonary-specific vasculopathy termed pulmonary intravascular coagulopathy (PIC) as distinct to DIC. Given that thrombotic risk is significantly impacted by race, coupled with the accumulating evidence that coagulopathy is important in COVID19 pathogenesis, our findings raise the intriguing possibility that pulmonary vasculopathy may contribute to the unexplained differences that are beginning to emerge highlighting racial susceptibility to COVID19 mortality.
Keywords: COVID19; D-dimer; coagulation parameter; novel coronavirus pneumonia.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Conflict of interest statement
JSO’D has served on the speaker’s bureau for Baxter, Bayer, Novo Nordisk, Boehringer Ingelheim, Leo Pharma, Takeda and Octapharma. He has also served on the advisory boards of Baxter, Bayer, Octapharma CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda and Pfizer. JSO’D has also received research grant funding awards from Baxter, Bayer, Pfizer, Shire, Takeda and Novo Nordisk.
Figures

Comment in
-
More on: 'COVID-19 coagulopathy in Caucasian patients'.Br J Haematol. 2020 Jun;189(6):1059-1060. doi: 10.1111/bjh.16772. Epub 2020 May 22. Br J Haematol. 2020. PMID: 32392353 Free PMC article. No abstract available.
-
Molecular mechanisms for thrombosis risk in Black people: a role in excess mortality from COVID-19.Br J Haematol. 2020 Jul;190(2):e78-e80. doi: 10.1111/bjh.16869. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32438458 Free PMC article. No abstract available.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical